This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine.
As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.
Contents
Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations
Chapter 1 - Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities - Mario A. Eisenberger and Fred Saad
Chapter 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm - Tian Zhang and Andrew J. Armstrong
Chapter 3. Molecular Mechanisms of Prostate Cancer Progression after Castration - William G. Nelson and Kenneth J. Pienta
Chapter 4. New Imaging Modalities - Steve Y. Cho, Seyed S. Dianat and Katarzyna Macura
Part II. TREATMENT - The Androgen Receptor Signaling Axis biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals
Chapter 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer - Heather H. Cheng and Bruce Montgomery
Chapter 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer - Jarett L. Feldman, Dana Rathkopf and Michael J. Morris
Chapter 7. Approaches Targeting Androgen Synthesis (CYP 17 inhibitors) - Adam Siegel and Charles J. Ryan
Chapter 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) - Robert J. van Soest, Ellen S. de Morrée, Cora N. Sternberg and Ronald de Wit
Chapter 9. The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer - Romulado Barroso-Sousa and Charles G. Drake
Chapter 10. Bone Targeted Therapy: Rationale and Current Status - Benjamin A. Gartrell and Fred Saad
Chapter 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer - Oliver Sartor and Brian Lewis
Part III. New Drug Development: Clinical Trials Design in CRPC
Chapter 12. Introduction - Aurelius Omlin, Carmel Pezaro and Johann S. de Bono
Chapter 13. Phase I/II targeted treatments - Aurelius Omlin, Carmel Pezaro and Johann S. de Bono
Chapter 14. Defining Clinical Endpoints in Castration-resistant Prostate Cancer - Jorge A. Garcia and Robert Dreicer
Part IV. New Drug Development: Specific Targets
Chapter 15. Angiogenesis Inhibition in Castration Resistant Prostate Cancer - Daniel J. George, William Kelly and Aaron Mitchell
Chapter 16. Co-targeting Adaptive Survival Pathways - Amina Zoubeidi and Martin Gleave
Chapter 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer - Hans J. Hammers and Emmanuel S. Antonarakis
Chapter 18. PARP Inhibitors - Joaquin Mateo, Timothy A. Yap and Johann S. De Bono
Chapter 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer - Petros D. Grivas and David C. Smith
Chapter 20. Epigenetics in Castration Resistant Prostate Cancer - Leigh Ellis, Sheng-Yu Ku, Elena Lasorsa and Roberto Pili
Chapter 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype - Himisha Beltran, Gurveen Kaur, Myriam Kossai, David M. Nanus and Scott T. Tagawa
Part V. Clinical Management Aspects
Chapter 22. Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management - Channing J. Paller and Thomas J. Smith
Chapter 23. Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development - Jacob A. Martin and William K. Oh